论文部分内容阅读
尽管世界生物制品与药品市场受到2001年美国“9·11”事件的很大影响,但生物技术与制药公司的研究与开发以及其产品开发计划仍有条不紊地进行。据总部设在旧金山的生命科学商品库(Burrill＆Company)的首席执行官布瑞(Burrill GS)认为,的确,2001年生物技术已趋向成熟并恢复其活力。 据《遗传工程新闻》(GEN)的年度报告报道,2002年世界生物技术与制药公司的市场资金表明,世界生物技术公司与制药公司的销售额都受到经济和华尔街股市的影响。从表1中可以看出,Amgen公司的市场资金为522.8亿美元,Genentech公司为185.3亿美元,Serono公司为179.7亿美元。这三家公司与其2001年的市场资金(分别为687.1亿美元,268.5亿美元
Although the world’s biological products and pharmaceuticals market was greatly affected by the 2001 “9.11” incident in the United States, the research and development of biotechnology and pharmaceutical companies and their product development plans are still proceeding in an orderly manner. According to Burrill GS, chief executive of San Francisco-based Burrill & Company, it is true that in 2001 biotechnology has matured and regained its vitality. According to the annual report of the Genetic Engineering News (GEN), market funds from biotech and pharmaceutical companies in the world in 2002 showed that the sales of biotech companies and pharmaceutical companies in the world are affected by the economy and Wall Street’s stock market. As can be seen from Table 1, Amgen’s market capitalization is 52.28 billion U.S. dollars, Genentech is 18.53 billion U.S. dollars, and Serono is 17.97 billion U.S. dollars. The three companies had their market funds in 2001 ($687.11 million and $26.85 billion, respectively)